|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2004-8-27
|
|
pubmed:abstractText |
New effective therapy is desirable for patients with non-small cell lung cancer (NSCLC) who have failed previous treatments. Fractionated administration of paclitaxel may be less toxic and more active against NSCLC. The aim of this study was to evaluate the activity and toxicity of weekly paclitaxel therapy for NSCLC in a second-line setting.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
pubmed-author:HitsudaYutakaY,
pubmed-author:IgishiTadashiT,
pubmed-author:KatayamaSatoruS,
pubmed-author:KatoKazuhiroK,
pubmed-author:KawasakiYujiY,
pubmed-author:MatsumotoShingoS,
pubmed-author:SakoTakanoriT,
pubmed-author:ShigeokaYasushiY,
pubmed-author:ShimizuEijiE,
pubmed-author:SugitaniAkinoriA,
pubmed-author:SuyamaHisashiH,
pubmed-author:YamamotoMistunobuM,
pubmed-author:YasudaKazuhitoK
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
347-52
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15331920-Adult,
pubmed-meshheading:15331920-Aged,
pubmed-meshheading:15331920-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:15331920-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:15331920-Female,
pubmed-meshheading:15331920-Humans,
pubmed-meshheading:15331920-Lung Neoplasms,
pubmed-meshheading:15331920-Male,
pubmed-meshheading:15331920-Middle Aged,
pubmed-meshheading:15331920-Paclitaxel,
pubmed-meshheading:15331920-Survival Analysis,
pubmed-meshheading:15331920-Treatment Failure,
pubmed-meshheading:15331920-Treatment Outcome
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments.
|
|
pubmed:affiliation |
Third Department of Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
